Share on StockTwits

Novartis AG (NYSE:NVS) shares hit a new 52-week high during mid-day trading on Tuesday , reports. The stock traded as high as $93.58 and last traded at $93.44, with a volume of 4,496,538 shares trading hands. The stock had previously closed at $89.84.

A number of research firms have recently commented on NVS. Analysts at Zacks reiterated a “neutral” rating on shares of Novartis AG in a research note on Friday, July 25th. They now have a $94.00 price target on the stock. Analysts at Barclays upgraded shares of Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Monday, June 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. Novartis AG presently has an average rating of “Hold” and a consensus price target of $93.67.

The stock’s 50-day moving average is $88.16 and its 200-day moving average is $86.70. The company has a market cap of $227.1 billion and a price-to-earnings ratio of 22.81.

Novartis AG (NYSE:NVS) last announced its earnings results on Thursday, July 17th. The company reported $1.36 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.36. The company had revenue of $14.64 billion for the quarter, compared to the consensus estimate of $14.83 billion. During the same quarter in the previous year, the company posted $1.30 earnings per share. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. Analysts expect that Novartis AG will post $5.14 EPS for the current fiscal year.

Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals.

Receive News & Ratings for Novartis AG (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.